KONEXBiotech & Pharma222670

Plumbline Life Sciences

₩4,635 0.00%2026-11-18 close
Market Cap
₩18.7B
Turnover
₩0
Volume
0 shares
Shares out.
4M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Canine Aging Drug Launched, Revenue Still Thin

Plumbline Life Sciences has secured approval and launched its canine aging therapy, yet 2025 revenue was only KRW 19.2 million and total equity remains negative.

  1. 1

    RenuDog received domestic product approval from the Animal and Plant Quarantine Agency in October 2024.

  2. 2

    Latest reported revenue, for 2025, was KRW 19.2 million. The operating loss for that year was KRW 1,269 million and the net loss was KRW 1,432 million.

  3. 3

    At the end of 2025, total assets were KRW 2,854 million, total liabilities KRW 6,921 million and total equity negative KRW 4,067 million.

  4. 4

    A domestic sales contract with Humanwellness, disclosed on April 3, 2026, was worth KRW 399,636,364.

  5. 5

    The CEO has said the company will prepare for a KOSDAQ transfer, including a technology evaluation, in 2026 and aim to meet requirements for 2027. Trading value is currently zero, so liquidity is effectively absent.

02

Business structure

Plumbline Life Sciences was founded in January 2014 and is a biotech venture that develops and produces DNA medicines tailored to specific animal species. It listed on the KONEX market on July 28, 2015. Its core product is RenuDog, a healthy-aging therapy for senior dogs.

RenuDog is a biologic that uses the canine GHRH gene sequence to regulate insulin-like growth factor (IGF-I) in line with the body's own homeostasis. The company said its Phase 3 trial in 30 dogs aged 10 or older showed increases of 33% in CD8+ naive T cells, 23% in appetite and 24% in activity.

The pipeline extends beyond RenuDog. PLS-D5000, a canine DNA cancer immunotherapy, has Phase 3 approval, and an African swine fever vaccine is at an early stage. LifeTide SW5, a DNA immunomodulator for sows, has product approvals in Australia, New Zealand and Korea, among others.

On the competitive side, the US start-up Loyal is developing LOY-002, a canine aging drug. A revenue breakdown by segment is not available from filings, and with RenuDog sales only just beginning in 2025, the business is effectively a single-product structure.

03

Recent trends

Per the filing, 2025 revenue was about KRW 19 million, with an operating loss of KRW 1,269 million and a net loss of KRW 1,432 million. The latest revenue figure the company disclosed is KRW 19.2 million.

In 2024 there was no revenue, the operating loss was KRW 3,130.57 million and the net loss was KRW 3,806.52 million. The loss narrowed in 2025, but the revenue base remains minimal.

At the end of 2025, total equity was negative KRW 4,067 million, and total liabilities of KRW 6,921 million exceeded total assets of KRW 2,854 million. On the commercial side, the company signed a domestic sales contract with Humanwellness on April 3, 2026, with a delivery period from April 3 to October 10, 2026.

No filing on 2026 quarterly results was confirmed, so none are described here. The share price has ranged between a 52-week low of KRW 4,200 and a high of KRW 6,950, and on October 8, 2026 the open, high, low and close were all KRW 4,635.

At the time of writing, the price is KRW 4,635, trading value is zero and market capitalization is KRW 18.7 billion.

04

Outlook

The key variables ahead are repeat purchases of RenuDog and the expansion of sales channels. The company targets domestic sales of more than KRW 10 billion within two years of launch and more than KRW 50 billion within five years.

These are management targets, and they sit far from actual 2025 revenue of KRW 19.2 million. IV Research had earlier estimated revenue of about KRW 3 billion for 2025 and KRW 10 billion for 2026.

On overseas strategy, the company plans to commercialize with partners in markets with lower clinical burdens and to pursue technology transfer for large markets such as the EU and the US. No filing confirming a technology transfer agreement was found.

On listing, the company plans to prepare for the transfer and undergo a technology evaluation in 2026, with 2027 as the target for meeting requirements. As for the market backdrop, the number of companies transferring to KOSDAQ in 2025 was four, the lowest in 11 years. The transfer therefore depends on improvement in revenue quality and financial requirements.

05

Bull factors

First-in-class approval and trial data

RenuDog received domestic product approval in October 2024. The company points to efficacy lasting up to six months from a single injection as a differentiator. According to the company, 17 of 23 caregivers in the Phase 3 trial said they would be willing to re-administer the drug. Having an approved product already distinguishes the company from many development-stage biotechs.

Sales contract as a commercialization signal

The KRW 399,636,364 Humanwellness contract equals 2,081.44% of the latest disclosed revenue of KRW 19.2 million. The contract includes down payments and advances, and the product is supplied in tranches according to requested quantities.

Press coverage also reported that contracts with veterinary hospitals had begun in earnest. The contract size itself is still small relative to the company's own medium-term targets.

Pipeline breadth and overseas strategy

Besides RenuDog, the company holds a canine cancer immunotherapy with Phase 3 approval and a swine immunomodulator with overseas approvals. The CEO has said that, starting with RenuDog, the company intends to introduce products for other companion animals such as cats.

For large markets such as the EU and the US, the company aims to rely on technology transfer to gain speed and efficiency. These remain plans, and no executed agreement has been confirmed.

06

Bear factors

Gap between targets and actual sales

The latest disclosed revenue is KRW 19.2 million. That is far from the roughly KRW 3 billion that IV Research had estimated for 2025. Commentary has also noted that RenuDog's commercialization came later than expected. It will take time before a repeat-purchase structure can be demonstrated.

Negative equity and funding needs

At the end of 2025, total equity was negative KRW 4,066.6 million, against total liabilities of KRW 6,921 million. In March 2025 the company disclosed the disposal of 42,134 treasury shares at KRW 5,610 per share to secure working capital. It also disclosed third-party allotment rights offerings in the same year. If operating losses continue, further fundraising and share dilution remain possible.

No trading and limited market attention

One report noted that more than half of KONEX stocks effectively see no trading. This stock also had zero trading value at the time of writing, which limits the meaning of the quoted price. One outlet described the market response as cool, with a market capitalization of only KRW 27 billion. Low liquidity reduces the reliability of price information and can make trading itself difficult.

07

Risk factors

Macro

Trading on the KONEX market is subdued. One analysis says the shrinking KONEX market has sharply reduced the pool of likely KOSDAQ transfer candidates. Only four companies transferred in 2025, the fewest in 11 years. If market conditions do not improve, the transfer timeline and funding conditions could be affected.

Industry

Canine aging therapeutics is still a developing market. The US company Loyal is developing LOY-002 and is valued at KRW 1 trillion. The same outlet cautioned that Loyal and Plumbline Life Sciences cannot be considered equivalent.

Progress by overseas competitors or regulatory changes could alter the conditions for technology transfer negotiations.

Company-specific

Revenue effectively depends on a single product, RenuDog. At the annual general meeting, approval of the financial statements was 41.4% of total voting shares issued. The company had planned sales to begin in the second half of 2025, and the actual pace of sales expansion needs further confirmation through filings. Future disclosures on sales channels and contract fulfilment should be monitored.

08

Overall view

Plumbline Life Sciences is an animal-medicine company that has obtained approval and begun selling in a new field, canine aging therapeutics. The clinical data and the sales contract are facts that show commercial progress.

At the same time, 2025 revenue of KRW 19.2 million, an operating loss of KRW 1,269 million and negative total equity of KRW 4,067 million point to a heavy financial burden.

The company's targets of KRW 10 billion and KRW 50 billion in sales are plans, and their achievement depends on confirming repeat purchases and sales-channel expansion. The KOSDAQ transfer is targeted for 2027, but a weak transfer market adds uncertainty to the timeline.

Because KONEX shares can go without trading, the reference value of the current price of KRW 4,635 is also limited. With bullish and bearish factors coexisting, readers are advised to verify subsequent filings and quarterly results themselves.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. kind.krx.co.kr
  2. m.news.nate.com
  3. m.news.nate.com
  4. edaily.co.kr
  5. pharm.edaily.co.kr
  6. pharm.edaily.co.kr
  7. press9.kr
  8. press9.kr
  9. dailyinvest.kr
  10. news.mt.co.kr
  11. eugenefn.com
  12. alphasquare.co.kr
  13. englishdart.fss.or.kr

Report written 2026-10-27 · Data as of 2026-10-26

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis